Affibody to start clinical development of a approach for the diagnosis of cancer
Swedish MPA gives go ahead for the clinical trial of Affibody's molecular imaging agent designed to improve the diagnosis of HER2-positive breast cancer.
28-Sep-2007 -
Affibody Holding AB has received a letter from the Swedish Medical Product Agency (MPA) allowing it to begin an exploratory clinical trial of a new approach for diagnosing an aggressive form of breast cancer. The approach, which is based on the Company's lead proprietary targeting Affibody® ...
breast cancer
clinical trials
membrane proteins
+3